[The inhibitory effect of the synthetic leu-enkephalin analog dalargin on carcinogenesis]

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Cancer remains a significant global health challenge, necessitating novel therapeutic strategies.
• Opioid peptides, such as Dalargin, are being investigated for their potential biological activities, including anti-cancer effects.

Purpose of the Study:

• To evaluate the efficacy of Dalargin in inhibiting chemical-induced carcinogenesis.
• To assess the impact of Dalargin on tumor latency, incidence, and specific cancer types.

Main Methods:

• Administration of Dalargin, an opioid peptide (Tyr-D-Ala-Gly-Phe-Leu-Arg), to subjects.
• Induction of carcinogenesis using a single intravenous injection of nitrosomethylurea (50 mg/kg body weight).
• Monitoring tumor development, latency period, and incidence of various neoplasms.

Main Results:

• Dalargin significantly inhibited the carcinogenic effects of nitrosomethylurea.
• A notable increase in the tumor latency period was observed following Dalargin treatment.
• Overall tumor incidence decreased by 20%, with malignant neoplasms and breast adenocarcinoma incidence reduced by 33% and 27%, respectively.
• Dalargin demonstrated a pronounced inhibitory effect on hematopoietic tumor induction.

Conclusions:

• Dalargin exhibits significant chemopreventive properties against nitrosomethylurea-induced carcinogenesis.
• The findings suggest Dalargin as a potential therapeutic agent for cancer prevention and treatment.
• Further research into the mechanisms of Dalargin's anti-cancer activity is warranted.